Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Bone Loss in Women With Anorexia Nervosa
This study has been completed.
Sponsors and Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00089843
  Purpose

Women with Anorexia Nervosa have been found to have low bone density. The study will determine whether administration of low doses of a natural hormone, testosterone and/or risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in this condition.


Condition Intervention Phase
Anorexia Nervosa
Drug: Testosterone
Drug: Risedronate
Phase II
Phase III

Drug Information available for: Insulin-like growth factor I Mecasermin rinfabate Testosterone Methyltestosterone Oxymesterone Testosterone enanthate Testosterone Propionate Testosterone undecanoate Risedronate sodium Risedronic acid
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Factorial Assignment, Efficacy Study
Official Title: IGF-1 and Bone Loss in Women Anorexia Nervosa

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • Bone density [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Bone markers [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]

Enrollment: 76
Study Start Date: June 2003
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
2: Placebo Comparator
Placebo Actonel and active testosterone patch
Drug: Testosterone
Testosterone patch 150mcg daily
3: Active Comparator
Active Actonel and Active Testosterone patch
Drug: Testosterone
Testosterone patch 150mcg daily
Drug: Risedronate
Risedronate 35mg PO one time weekly
4: Active Comparator
Active Actonel and Placebo Testosterone
Drug: Risedronate
Risedronate 35mg PO one time weekly
1: No Intervention
Placebo testosterone patch and placebo actonel

Detailed Description:

II. SPECIFIC AIMS

Severe osteopenia is a prevalent complication of anorexia nervosa (AN), affecting over half of all women with this disease. Loss of 25-50% of total bone mass occurs frequently and is often permanent. Although anorexia nervosa affects from 0.5-1.0% of college age women, no successful therapeutic interventions have been developed for osteoporosis in this population. Bone loss in anorexia nervosa is characterized by reduced bone formation coupled with increased bone resorption. Anorexia nervosa results in a deficiency of testosterone. Testosterone administration reduces bone resorption and data suggest that low-dose testosterone replacement therapy can increase surrogate markers of bone formation. Bisphosphonates are now well established to decrease bone resorption and improve bone density in severely osteopenic postmenopausal women. However, there are few data regarding the use of this antiresorptive therapy in women with severe pre-menopausal bone loss. Our preliminary data demonstrate that administration of a bisphosphonate decreases bone resorption and increases bone mass in women with AN after 6 and 9 months. These are the first data to demonstrate a striking increase in bone density in such women. We will test the hypothesis that a combined strategy to increase bone formation and decrease bone resorption by combining testosterone with a bisphosphonate will increase bone mass in anorexia nervosa.

The following hypotheses will be tested:

Specific Aim 1. Testosterone, a nutritionally dependent bone trophic factor, is a critical determinant of decreased bone formation in anorexia nervosa, and administration of physiologic testosterone will increase bone formation and lean body mass in this disease

We will investigate in women with anorexia nervosa whether:

A. Bone formation is reduced in association with low serum testosterone B. Testosterone deficiency is due to a combination of ovarian and adrenal defects resulting from undernutrition C. Testosterone administration reverses testosterone deficiency leading to an acute and sustained increase in bone formation and a decrease in bone resorption D. Administration of physiologic testosterone replacement stimulates increases in IGF-I levels in women with anorexia nervosa, a mechanism for increased bone formation and bone density E. Administration of physiologic testosterone replacement increases lean body mass, a major determinant of bone density

Specific Aim 2. Long-term (12 months) physiologic testosterone administration combined with a bisphosphonate increases bone density by a dual anabolic and anti-resorptive strategy

We will investigate in women with anorexia nervosa whether:

A. Physiologic testosterone administration increases bone density B. Administration of a bisphosphonate decreases the excessive state of bone resorption and increases bone density C. Co-administration of physiologic testosterone replacement and a bisphosphonate increases bone density to a greater degree than testosterone or a bisphosphonate alone by increasing bone formation and decreasing bone resorption

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Anorexia Nervosa,
  • Over 18,
  • Female,
  • Decreased bone density

Exclusion Criteria:

  • Medications to increase bone density
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00089843

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Investigators
Principal Investigator: Anne Klibanski, M.D. Massachusetts General Hospital
  More Information

Publications indexed to this study:
Responsible Party: Massachusetts General Hospital ( Christine Holley-Williams / Senior Grants and Contracts Administrator )
Study ID Numbers: 5 R01 DK052625-07
Study First Received: August 16, 2004
Last Updated: August 22, 2008
ClinicalTrials.gov Identifier: NCT00089843  
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Eating Disorders
Osteopenia

Study placed in the following topic categories:
Calcium, Dietary
Signs and Symptoms
Testosterone
Signs and Symptoms, Digestive
Mental Disorders
Anorexia
Methyltestosterone
Anorexia Nervosa
Risedronic acid
Eating Disorders
Testosterone 17 beta-cypionate

Additional relevant MeSH terms:
Antineoplastic Agents, Hormonal
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Calcium Channel Blockers
Bone Density Conservation Agents
Cardiovascular Agents
Hormones
Pharmacologic Actions
Membrane Transport Modulators
Anabolic Agents
Therapeutic Uses
Androgens

ClinicalTrials.gov processed this record on January 14, 2009